To The Moon

$IONQ Inc.(IONQ)$ 's Revenue Grew 287% — So Why Do Analysts Still Disagree by $51 a Share? August 15, 2026

IonQ just posted the best quarter in its history, beat revenue estimates by roughly 20%, and raised its full-year outlook — and the stock has responded by ripping higher, up sharply from where it sat before earnings. But ask five analysts where it goes from here and you'll get five different answers, ranging from a company barely worth more than it trades for today to one worth more than double. Before SPR's technical coverage on IONQ updates next week, here's the fundamental picture: what actually happened last quarter, how Wall Street is pricing it, and why the valuation debate on this one is far from settled.

The News Behind the Move

Imagine running a company that's roughly quadrupled its revenue in a year while still losing money on every dollar of it — that's the tension sitting at the center of IonQ's story right now. For the second quarter of 2026, the company reported record revenue of $80.1 million, a 287% year-over-year increase that landed about 20% above the midpoint of its own guidance, marking its fifth consecutive quarter of record results. Management didn't just beat the quarter — it raised its full-year 2026 revenue guidance to $280–290 million, comfortably above the roughly $268 million analysts had penciled in.

The government side of the business is quietly becoming a real growth engine. IonQ's Capella space subsidiary won a National Reconnaissance Office contract to supply commercial synthetic-aperture-radar imagery for national-security missions, and separately, DARPA extended IonQ's contract with an additional $28 million to expand production of its Evergreen-05 optical atomic clocks — hardware used in radar, secure communications, and precision navigation. Layered on top of that, IonQ completed its acquisition of SkyWater Technology, a domestic chip manufacturer, in an all-stock deal, a move aimed at giving the company more control over its own hardware production pipeline. The one number that muddies the picture: GAAP net loss for the quarter came in at a startling $1.87 billion, but the bulk of that was a $1.6 billion non-cash, mark-to-market charge tied to the fair value of warrant liabilities — an accounting artifact, not a cash outflow, though it's the kind of headline number that can spook a reader who doesn't dig into the footnotes.

What Wall Street Analysts Are Saying

Read enough of these notes back to back and a pattern shows up: almost nobody is bearish on IonQ's business, but there's real disagreement about what it's worth today.

• Rosenblatt Securities (John McPeake) — reaffirmed Buy, $100 target, the most bullish figure in coverage

• Jefferies — trimmed its target to $75 from $85 even after the beat, still implying substantial upside from current levels

• Cantor Fitzgerald (Troy Jensen) — maintained Overweight, $70 target, modeling a path to roughly 30% share of the quantum hardware, software, and services market by 2035

• Needham (Quinn Bolton) — reiterated Buy, $65 target, highlighting that international customers made up about half of quarterly revenue

• Morgan Stanley — raised its target modestly to $49 from $48.50, but kept an Equal Weight rating

• JPMorgan (Mayur Ramdhani) — reiterated a Neutral stance

That's a spread running from the high $40s to $100 — a gap of roughly $51 between the most cautious and most bullish targets, which tells you the disagreement isn't about whether the business is growing, it's about how much to pay today for revenue that's still years away from turning into durable profit.

Is IONQ Overvalued or Undervalued?

Here's where the numbers get genuinely hard to reconcile. IonQ trades at a trailing price-to-sales ratio of roughly 62 — steep by almost any conventional standard, but actually a meaningful compression from where the multiple sat earlier this year, purely because revenue has been growing faster than the share price. Look at it from a forward-looking angle instead: at a market cap near $18–19 billion, the stock is being valued at somewhere around 50 times the midpoint of this year's own revenue guidance. That's the kind of multiple that only makes sense if triple-digit growth continues well past 2026.

The balance sheet is the counterweight to that valuation anxiety. IonQ is sitting on roughly $2.1 billion in cash against just $54.5 million in debt — a net cash position of about $5.53 per share — with a current ratio above 10, meaning near-term obligations aren't remotely a concern. Set against that, return on equity sits at around -60% and return on invested capital near -26%, a reminder that the company is still burning meaningfully to fund its growth. The Altman Z-Score of 2.37 lands in what's typically called the "grey zone" — not distress territory, but not the safety of an established, cash-generative business either. In short: the company likely isn't going anywhere, but the stock's price still requires investors to believe in a growth story that hasn't finished playing out.

The Risk Variables Investors Should Watch

Three threads worth following past next week:

Dilution is an ongoing, structural risk, not a one-time event. The SkyWater deal was funded largely in stock, and IonQ recently filed a prospectus supplement covering potential further share issuance — shares outstanding have already climbed roughly 50% over the past year, and a company still burning cash at this scale tends to keep leaning on equity markets.

The valuation gap between bulls and skeptics is unusually wide for a stock this closely covered. When Morgan Stanley and Rosenblatt Securities are more than $50 apart on the same ticker with the same quarter in hand, it signals a genuine disagreement about growth durability — not just rounding differences in a spreadsheet.

Competitive and volatility risk stays elevated. IonQ carries a beta above 3, meaning it tends to move roughly three times as much as the broader market in either direction, and short interest sits near 12.6% of the float — a level that can amplify moves in both directions when sentiment shifts.

If the Story Shifts Before the Next Print

Suppose the SkyWater integration starts translating into visible margin improvement, or another marquee government contract lands the way the DARPA and NRO deals did — that's the scenario where the Rosenblatt and Jefferies camps look prescient, and more analysts drift toward the higher end of the range. Now suppose instead that revenue growth decelerates from the 287% pace, or the cash burn accelerates faster than guidance implies — that's the scenario where the Morgan Stanley and JPMorgan caution starts to look like the correct read, and the 50-times-sales multiple becomes harder to defend. Which of those paths the stock actually leans toward — and where buyers and sellers are drawing their lines — is exactly what next week's technical coverage is built to capture.